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Usually, empirical reports involve groups of patients; the individual patient perspective is overlooked. To fill this gap, in this paper we advocate a practical, patient-oriented approach to mania.
G AP B E T WEEN G U IDELINE S AND CLINI C AL PR AC TI CE
Multiple studies have shown that the majority of bipolar patients are routinely treated with antidepressants for their depression. A recent meta-analysis also showed that SSRI addition to lithium is superior over placebo in short-term regimes. 2 The hesitation to award antidepressants a more prominent role in the guidelines stems from the notion that they may induce (hypo) mania, particularly TCAs and venlafaxine. The risk of SSRIs triggering (hypo)mania is considered to be much lower, however, especially when they are combined with mood stabilizers.
1 Moreover, it is by no means certain that the mania switches are caused by the antidepressants. Previous research showed that, rather than being medicationrelated, the switch process in bipolar disorder may be an artefact of the depressive episodes lasting less long with resulting relapses into mania. Nevertheless, reviews and guidelines repeatedly warn against this effect, likely prompted by the ethical imperative to "first do no harm". Experts have particularly discouraged long-term regimens because of the potentially adverse effect on disease progression, including manic switches or the induction of a rapid cycling pattern.
NOT ALL (HYP O) MANIA S ARE HARMFUL
We propose an alternative explanation for the widespread use of antidepressants in bipolar disorder. First, as a result of the present shared decision-making paradigm, personal considerations and subjective balancing of risks have become a focus of attention. It is possible that the clinician and/or the patient do not judge the risk of manic switches to be a relevant consideration in their specific situation. As mentioned above, for most bipolar patients the prevention of depressive episodes has high priority. Although the potential harm of mania is indisputable, it has been shown that patients judge the burden of the depression to be significantly higher than the burden of the manic episodes, 3 while for most the depressive episodes last substantially longer.Therefore, we can assume that the severity of depression is weighted differently in relation to the risk of mania, in the final treatment decisions patients and clinicians make. 
HOW HARMFUL IS MANIC EPISODE?
To determine how harmful mania is to a patient or his/her envi- 
